Karyopharm Therapeutics Stock Z Score
| KPTI Stock | USD 1.09 0.04 3.54% |
Karyopharm | Z Score |
Karyopharm Therapeutics Company Z Score Analysis
Karyopharm Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Karyopharm Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Karyopharm Therapeutics is extremely important. It helps to project a fair market value of Karyopharm Stock properly, considering its historical fundamentals such as Z Score. Since Karyopharm Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Karyopharm Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Karyopharm Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Karyopharm Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Karyopharm Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karyopharm Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics of similar companies.Karyopharm Therapeutics is currently under evaluation in z score category among related companies.
Karyopharm Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Karyopharm Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Karyopharm Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Karyopharm Therapeutics' value.| Shares | Marshall Wace Asset Management Ltd | 2023-12-31 | 1.9 M | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 1.8 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.7 M | Millennium Management Llc | 2023-12-31 | 1.5 M | Cam Group Holding A/s | 2023-12-31 | 1.5 M | Deutsche Bank Ag | 2023-12-31 | 1.3 M | Jpmorgan Chase & Co | 2023-12-31 | 1.2 M | Alphacentric Advisors, Llc | 2023-12-31 | 1.1 M | Tejara Capital Ltd | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 10.1 M | Vanguard Group Inc | 2023-12-31 | 8.7 M |
Karyopharm Fundamentals
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.98) % | ||||
| Operating Margin | (1.12) % | ||||
| Current Valuation | 248.08 M | ||||
| Shares Outstanding | 116.47 M | ||||
| Shares Owned By Insiders | 4.40 % | ||||
| Shares Owned By Institutions | 67.41 % | ||||
| Number Of Shares Shorted | 22.95 M | ||||
| Price To Earning | (3.90) X | ||||
| Price To Book | 12.05 X | ||||
| Price To Sales | 0.96 X | ||||
| Revenue | 146.03 M | ||||
| Gross Profit | 151.86 M | ||||
| EBITDA | (129.01 M) | ||||
| Net Income | (143.1 M) | ||||
| Cash And Equivalents | 170.85 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 177.02 M | ||||
| Debt To Equity | 2.59 % | ||||
| Current Ratio | 3.88 X | ||||
| Book Value Per Share | (1.19) X | ||||
| Cash Flow From Operations | (92.72 M) | ||||
| Short Ratio | 17.36 X | ||||
| Earnings Per Share | (1.25) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 5.57 | ||||
| Number Of Employees | 325 | ||||
| Beta | 0.056 | ||||
| Market Capitalization | 126.95 M | ||||
| Total Asset | 240.44 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 164.44 M | ||||
| Current Asset | 130.25 M | ||||
| Current Liabilities | 14.95 M | ||||
| Net Asset | 240.44 M |
About Karyopharm Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karyopharm Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Karyopharm Therapeutics Piotroski F Score and Karyopharm Therapeutics Valuation analysis. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.25) | Revenue Per Share 1.279 | Quarterly Revenue Growth 0.005 | Return On Assets (0.27) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.